{"schema_version":"secwatch.filing_event.v1","accession":"0001494650-24-000042","form_type":"8-K","ticker":null,"cik":"0001494650","company_name":"OptiNose, Inc.","filed_at":"2024-04-25T23:59:59+00:00","discovered_at":"2026-05-14T18:03:18.653892+00:00","generated_at":"2026-06-03T07:53:36.301071+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Optinose reports Q1 XHANCE revenue $14.9M (+26% YoY); sees peak >$300M","bullets":["Q1 2024 XHANCE net revenue $14.9M, up ~26% vs Q1 2023.","FDA approved XHANCE as first drug treatment for chronic sinusitis without nasal polyps.","Expects peak XHANCE net revenue >$300M; positive GAAP ops income by FY2025.","Leveraging 75 sales territories to target 3M patients; limited incremental spend.","Plans to use specialty pharmacy hub to improve prescription fill and reimbursement."],"urls":{"canonical":"https://secwatch.observer/filing/0001494650-24-000042","json":"https://secwatch.observer/filing/0001494650-24-000042.json","markdown":"https://secwatch.observer/filing/0001494650-24-000042.md","text":"https://secwatch.observer/filing/0001494650-24-000042.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1494650/000149465024000042/0001494650-24-000042-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1494650/000149465024000042/optn-20240425.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-03T07:53:36.301071+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"65531023a4c107d4a4975e5cfb40354a0380f463","claim":"OptiNose, Inc. reported the three months ended March 31, 2024 results: revenue $14.9 million. Guidance initiated.","evidence_excerpt":"the Company announced preliminary XHANCE net product revenue of $14.9 million for the three months ended March 31, 2024","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1494650/000149465024000042/0001494650-24-000042-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the three months ended March 31, 2024"},{"label":"Revenue","value":"$14.9 million"},{"label":"Guidance","value":"initiated"},{"label":"Result","value":"preliminary results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}